These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31834357)

  • 21. Stimulation of the sympathetic perimesenteric arterial nerves releases neuropeptide Y potentiating the vasomotor activity of noradrenaline: involvement of neuropeptide Y-Y1 receptors.
    Donoso MV; Brown N; Carrasco C; Cortes V; Fournier A; Huidobro-Toro JP
    J Neurochem; 1997 Sep; 69(3):1048-59. PubMed ID: 9282927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
    Silva AP; Carvalho AP; Carvalho CM; Malva JO
    Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Gibson CM; Pride YB; Buros JL; Lord E; Shui A; Murphy SA; Pinto DS; Zimetbaum PJ; Sabatine MS; Cannon CP; Josephson ME;
    J Am Coll Cardiol; 2008 Feb; 51(5):546-51. PubMed ID: 18237683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials.
    Hoedemaker NP; Roolvink V; de Winter RJ; van Royen N; Fuster V; García-Ruiz JM; Er F; Gassanov N; Hanada K; Okumura K; Ibáñez B; van 't Hof AW; Damman P
    Eur Heart J Acute Cardiovasc Care; 2020 Aug; 9(5):469-477. PubMed ID: 30759994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of ventricular fibrillation at reperfusion in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Demidova MM; Carlson J; Erlinge D; Platonov PG
    Am J Cardiol; 2015 Feb; 115(4):417-22. PubMed ID: 25549882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratification for complex ventricular arrhythmia complicating ST-segment elevation myocardial infarction.
    Podolecki TS; Lenarczyk RK; Kowalczyk JP; Jedrzejczyk-Patej EK; Chodor PK; Mazurek MH; Francuz PJ; Streb WA; Mitrega KA; Kalarus ZF
    Coron Artery Dis; 2018 Dec; 29(8):681-686. PubMed ID: 30234552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nur77 protects against adverse cardiac remodelling by limiting neuropeptide Y signalling in the sympathoadrenal-cardiac axis.
    Medzikovic L; van Roomen C; Baartscheer A; van Loenen PB; de Vos J; Bakker ENTP; Koenis DS; Damanafshan A; Creemers EE; Arkenbout EK; de Vries CJM; de Waard V
    Cardiovasc Res; 2018 Oct; 114(12):1617-1628. PubMed ID: 29850786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials.
    Sun B; Wang CY; Chen RR
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):833-846. PubMed ID: 37002468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of β-adrenergic receptors.
    van Weperen VYH; Hoang JD; Jani NR; Khaky A; Herring N; Smith C; Vaseghi M
    J Physiol; 2024 Feb; ():. PubMed ID: 38352977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone.
    Franco-Cereceda A; Lundberg JM; Dahlöf C
    Acta Physiol Scand; 1985 Jul; 124(3):361-9. PubMed ID: 3840319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.
    Mehta RH; Starr AZ; Lopes RD; Hochman JS; Widimsky P; Pieper KS; Armstrong PW; Granger CB;
    JAMA; 2009 May; 301(17):1779-89. PubMed ID: 19417195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.
    Gibbs JL; Diogenes A; Hargreaves KM
    Br J Pharmacol; 2007 Jan; 150(1):72-9. PubMed ID: 17143304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid measurement of cardiac neuropeptide dynamics by capacitive immunoprobe in the porcine heart.
    Kluge N; Dacey M; Hadaya J; Shivkumar K; Chan SA; Ardell JL; Smith C
    Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H66-H76. PubMed ID: 33095651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventricular Arrhythmias After Primary Percutaneous Coronary Intervention for STEMI.
    Rymer JA; Wegermann ZK; Wang TY; Li S; Smilowitz NR; Wilson BH; Jneid H; Tamis-Holland JE
    JAMA Netw Open; 2024 May; 7(5):e2410288. PubMed ID: 38717772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of inducible very fast ventricular tachycardia (cycle length 200-230 ms) after early reperfusion for ST-segment-elevation myocardial infarction.
    Zaman S; Kumar S; Sullivan J; Narayan A; Thiagalingam A; Ross DL; Kovoor P
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):884-90. PubMed ID: 23995117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y contributes to innervation-dependent increase in I(Ca, L) via ventricular Y2 receptors.
    Protas L; Robinson RB
    Am J Physiol; 1999 Sep; 277(3):H940-6. PubMed ID: 10484414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart.
    Ilebekk A; Björkman JA; Nordlander M
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):474-80. PubMed ID: 16160600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y and ATP interact to control renovascular resistance in the rat.
    Oberhauser V; Vonend O; Rump LC
    J Am Soc Nephrol; 1999 Jun; 10(6):1179-85. PubMed ID: 10361855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropeptide Y suppresses thermogenic and cardiovascular sympathetic nerve activity via Y1 receptors in the paraventricular nucleus and dorsomedial hypothalamus.
    Shi Z; Bonillas AC; Wong J; Padilla SL; Brooks VL
    J Neuroendocrinol; 2021 Aug; 33(8):e13006. PubMed ID: 34235800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ventricular fibrillation induced by ischemia-reperfusion is not prevented by the NPY Y2 receptor antagonist BIIE0246.
    Ilebekk A; Eriksen M; Sevre K; Aspelin T; Björkman JA; Lyberg T; Nordlander M
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):177-83. PubMed ID: 17056830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.